Khadijeh Abhari1, Saeede Saadati1, Fatemeh Hosseini-Oskouiee1, Zahra Yari1, Hedayat Hosseini2, Golbon Sohrab1, Ehsan Hejazi1, Shahram Agah3, Amir Sadeghi4, Azita Hekmatdoost5. 1. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Food Technology, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran. 4. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran. a_hekmat2000@yahoo.com.
Abstract
PURPOSE: The aim of this study was to assess the superiority of low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) diet plus Bacillus coagulans supplementation to low FODMAP diet alone in the reduction of irritable bowel syndrome (IBS) symptoms. METHODS: In this randomized clinical trial, fifty IBS patients who met Rome IV criteria for IBS were randomly assigned to receive a low FODMAP diet plus either a probiotic or a placebo capsule for 8 weeks. Probiotic capsules contained 109B. coagulans spores and 400 mg inulin, while placebo capsules consisted of 500 mg rice starch. RESULTS: Significant improvements were observed in abdominal pain intensity and frequency, abdominal distension, satisfaction with bowel habits, quality of life, defecation consistency, and patient-reported severity score in both groups; however, only improvement in severity score was significantly higher in probiotic group compared with placebo group (P = 0.001). Moreover, the frequency of patients with clinical improvement in IBS-symptom severity scale (IBS-SSS) was significantly more in probiotic group compared to placebo group (P = 0.038). CONCLUSION: Our results indicate that the addition of probiotic supplement containing B. coagulans to the low FODMAP diet might be superior to low FODMAP diet in alleviating IBS symptoms.
RCT Entities:
PURPOSE: The aim of this study was to assess the superiority of low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) diet plus Bacillus coagulans supplementation to low FODMAP diet alone in the reduction of irritable bowel syndrome (IBS) symptoms. METHODS: In this randomized clinical trial, fifty IBSpatients who met Rome IV criteria for IBS were randomly assigned to receive a low FODMAP diet plus either a probiotic or a placebo capsule for 8 weeks. Probiotic capsules contained 109B. coagulans spores and 400 mg inulin, while placebo capsules consisted of 500 mg ricestarch. RESULTS: Significant improvements were observed in abdominal pain intensity and frequency, abdominal distension, satisfaction with bowel habits, quality of life, defecation consistency, and patient-reported severity score in both groups; however, only improvement in severity score was significantly higher in probiotic group compared with placebo group (P = 0.001). Moreover, the frequency of patients with clinical improvement in IBS-symptom severity scale (IBS-SSS) was significantly more in probiotic group compared to placebo group (P = 0.038). CONCLUSION: Our results indicate that the addition of probiotic supplement containing B. coagulans to the low FODMAP diet might be superior to low FODMAP diet in alleviating IBS symptoms.
Authors: Alexander C Ford; Paul Moayyedi; William D Chey; Lucinda A Harris; Brian E Lacy; Yuri A Saito; Eamonn M M Quigley Journal: Am J Gastroenterol Date: 2018-06 Impact factor: 10.864
Authors: Edna P Nyangale; Sean Farmer; Howard A Cash; David Keller; David Chernoff; Glenn R Gibson Journal: J Nutr Date: 2015-05-06 Impact factor: 4.798
Authors: Joanna Dionne; Alexander C Ford; Yuhong Yuan; William D Chey; Brian E Lacy; Yuri A Saito; Eamonn M M Quigley; Paul Moayyedi Journal: Am J Gastroenterol Date: 2018-07-26 Impact factor: 10.864
Authors: Alexander C Ford; Eamonn M M Quigley; Brian E Lacy; Anthony J Lembo; Yuri A Saito; Lawrence R Schiller; Edy E Soffer; Brennan M R Spiegel; Paul Moayyedi Journal: Am J Gastroenterol Date: 2014-07-29 Impact factor: 10.864
Authors: Heidi Maria Staudacher; Miranda C E Lomer; Freda M Farquharson; Petra Louis; Francesca Fava; Elena Franciosi; Matthias Scholz; Kieran M Tuohy; James O Lindsay; Peter M Irving; Kevin Whelan Journal: Gastroenterology Date: 2017-06-15 Impact factor: 22.682